Recent reports revealed that NICE has advised adults suffering from deep vein thrombosis (DVT) to take rivaroxaban, as a treatment for the condition. The Bayer’s produced drug Xarelto has to be taken orally and it has been administered that it not only treats the condition but also prevents it.

Recently the health regulators stated in their final guidance: “Xarelto is now an option for treating deep vein thrombosis and preventing recurrent deep vein thrombosis and pulmonary embolism in adults diagnosed with acute DVT”.

However, previously NICE was not in favor of recommending the pill, they claimed that the drug needs to provide with more evidences to support its worth as a treatment for the condition.

In response to this, Bayer provided the health regulators with the suitable and appropriate efficacy data that supported the drug and hence, was approved to be used as a treatment.

Professor Carole Longson, NICE health technology evaluation centre director, asserted that the previously used treatment drug for the condition, warfarin was not successful in majority cases of the patients, as the pill demanded of proper tests at regular intervals, including blood tests, proper diet, as the drug could not be taken with all foods.

However, this new drug has overcome the drawbacks of the previous pill, hence is believed to be a suitable treatment.